There are many challenges in the pharmaceutical supply chain, from maintaining quality to security issues. Can blockchain provide the end-to-end visibility needed? It’s a good time for the ...

The biopharma industry loses approximately $35 billion annually due to failures in temperature-controlled logistics,” he ...

Supply chain operating network New strategies use the experience of consumer product companies but take into account the specifics of the pharma industry. A cloud-based network to enable end-to ...

The pharmaceutical industry faces significant challenges with supply chain waste, affecting both environmental sustainability ...

The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

DUBLIN--(BUSINESS WIRE)--The "Pharma ... the supply chain from various points at different levels. Pharmaceutical companies that adopt an effective serialisation program have end-to-end visibility ...

There is a pressing need for CDMOs to address these supply chain challenges in a volatile, uncertain, complex, and ambiguous (VUCA) environment, and to implement strategies for resilience in the face ...

Creating a well-integrated, resilient, and highly transparent supply chain is central to effective and safe patient ... the health condition and how it is managed. That process may start and end with ...

Based on these figures and the overall market size, it could be concluded that the pharmaceutical supply-chain management is ... connections and this itch to start up. We even came up with two ...

In an era where a global pharma ... supply lines in the sector. This led to companies adopting several sustainability ...

Bachem's Pascal Degen explains the challenges faced by CDMOs in a volatile, uncertain, complex and ambiguous (VUCA) world.